Schistosoma haematobium treatment in 1-5 year old children: safety and efficacy of the antihelminthic drug praziquantel.
Morbidity due to schistosomiasis is currently controlled by treatment of schistosome infected people with the antihelminthic drug praziquantel (PZQ). Children aged up to 5 years are currently excluded from schistosome control programmes largely due to the lack of PZQ safety data in this age group. T...
Saved in:
Main Authors: | Francisca Mutapi (Author), Nadine Rujeni (Author), Claire Bourke (Author), Kate Mitchell (Author), Laura Appleby (Author), Norman Nausch (Author), Nicholas Midzi (Author), Takafira Mduluza (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2011-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chitinase 3-like 1 protein levels are elevated in Schistosoma haematobium infected children.
by: Laura J Appleby, et al.
Published: (2012) -
Cytokine responses to the anti-schistosome vaccine candidate antigen glutathione-S-transferase vary with host age and are boosted by praziquantel treatment.
by: Claire D Bourke, et al.
Published: (2014) -
Age-related patterns in human myeloid dendritic cell populations in people exposed to Schistosoma haematobium infection.
by: Norman Nausch, et al.
Published: (2012) -
CD16 expression on monocytes in healthy individuals but not schistosome-infected patients is positively associated with levels of parasite-specific IgG and IgG1.
by: Laura J Appleby, et al.
Published: (2014) -
Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.
by: Kate M Mitchell, et al.
Published: (2014)